Actively Recruiting
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
Led by Chinese Academy of Medical Sciences · Updated on 2018-12-12
300
Participants Needed
1
Research Sites
469 weeks
Total Duration
On this page
Sponsors
C
Chinese Academy of Medical Sciences
Lead Sponsor
T
The First Affiliated Hospital with Nanjing Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Currently, adjuvant therapy is not recommended for patients with esophageal squamous cell carcinoma who received radical surgery. However, the recurrence rate is as high as 23.8%-58%, and the median time-to-recurrence is about 10.5 months. In patients who had residual tumor after surgery, evidence lacks for chemoradiation. The aim of the study is to evaluate the efficacy and safety of chemoradiation therapy in patients with recurrences after radical surgery or palliative surgery.
CONDITIONS
Official Title
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Locoregional recurrence after radical surgery
- Positive resection margin (R1/R2) after surgery
- Out-of-field recurrence after adjuvant chemoradiation or radiotherapy
- Recurrence after adjuvant chemotherapy
- No prior therapy after recurrence
- Age 16 to 70 years
- Karnofsky performance status greater than 70
- No history of drug allergy
- Sufficient liver and kidney functions
- White blood cell count greater than 4.0 x 10^9/L
You will not qualify if you...
- Age under 16 or over 70 years
- Pregnancy or lactation
- History of drug allergy
- Declining informed consent
- Insufficient liver or kidney functions, or abnormal complete blood count test
- Severe cardiovascular diseases, infections, active ulcerations
- Diabetes mellitus with unstable blood sugar
- Mental disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
Research Team
Z
Zefen Xiao, MD
CONTACT
L
Lei Deng, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here